v3.26.1
STOCKHOLDERS' EQUITY
 6 Months Ended
Jun. 30, 2026
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY
Stock-Based Compensation
The Company’s results for the three and six months ended June 30, 2026 and 2025 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

Increase/(Decrease) for theIncrease/(Decrease) for the
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Cost of sales$647 $536 $1,178 $974 
Operating expenses5,274 5,302 10,099 8,674 
Net earnings(4,580)(4,577)(8,700)(7,506)

The Company's omnibus incentive plan ("the Plan") allows for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plan. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of June 30, 2026, the Plan had 505,548 shares available for future awards.
Accounting Standards Codification ("ASC") 718, "Compensation-Stock Compensation", requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The weighted average fair values of the stock options granted under the Plan were calculated using either the Black-Scholes model or the Binomial model, whichever was deemed to be most appropriate. For the six months ended June 30, 2026, the fair value of each option grant was estimated on the date of the grant using the following weighted average assumptions:
 Six Months Ended June 30,
 20262025
Dividend yields0.5 %0.6 %
Expected volatilities23.5 %26.0 %
Risk-free interest rates3.8 %4.5 %
Expected lives5.2 years5.2 years
Option activity for the six months ended June 30, 2026 and 2025 is summarized below:
For the Six Months Ended June 30, 2026Shares (000s)Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding as of December 31, 2025900 $120.48 $29,888 5.2
Granted71 178.68 
Exercised(77)100.34 
Forfeited(1)143.43 
Canceled(2)139.31 
Outstanding as of June 30, 2026891 $126.79 $38,255 5.3
Exercisable as of June 30, 2026642 $115.27 $34,455 4.3
For the Six Months Ended June 30, 2025Shares (000s)Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding as of December 31, 2024962 $114.81 $46,346 5.8
Granted51 159.18 
Exercised(68)91.48 
Forfeited— — 
Canceled— — 
Outstanding as of June 30, 2025945 $118.88 $38,084 5.6
Exercisable as of June 30, 2025638 $106.87 $33,375 4.4

Other information pertaining to option activity during the three and six months ended June 30, 2026 and 2025 is as follows:

 Three Months Ended June 30,Six Months Ended June 30,
 2026202520262025
Weighted-average fair value of options granted$— $— $48.90 $48.86 
Total intrinsic value of stock options exercised ($000s)$813 $3,370 $5,567 $4,759 
The Company has Restricted Stock Grant Agreements with the Company's non–employee directors and certain employees, which are subject to time-based vesting requirements. The value of the restricted shares is based on the fair value of the award at the date of grant.
Non-vested restricted stock activity for the six months ended June 30, 2026 and 2025 is summarized below:
Six Months Ended June 30,
20262025
Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance as of December 31147 $150.15 122 $141.62 
Granted62 177.50 54 159.14 
Vested(51)144.89 (30)137.83 
Forfeited(5)154.65 (1)145.96 
Non-vested balance as of June 30153 $162.86 145 $148.91 
The Company also has performance share (“PS”) awards, which provide the recipients the right to receive a certain number of shares of the Common Stock in the future, subject to certain performance hurdles, depending on the date of the grant: (1) an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period (typically three years), (2) a relative total shareholder return (“TSR”) market condition where vesting is dependent upon the Company’s TSR performance over the performance period (typically three years) relative to a comparator group consisting of the Russell 2000 index constituents, or (3) an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period (typically three years) and modified based on the Company's TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. Expense is measured based on the fair value of the grant at the date of grant. A Monte-Carlo simulation has been used to estimate the fair value using the following assumptions:
 Six Months Ended June 30,
 20262025
Dividend yields— %— %
Expected volatilities22.8 %25.5 %
Risk-free interest rates3.5 %4.3 %
Initial TSR's16.0 %-8.8 %
Non-vested performance share activity for the six months ended June 30, 2026 and 2025 is summarized below:

Six Months Ended June 30,
20262025
Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance as of December 3181 $160.14 79 $150.73 
Granted50 173.60 50 147.96
Vested(35)148.64 (44)130.29
Forfeited— — (4)152.69
Non-vested balance as of June 3096 $171.52 81 $160.14 

As of June 30, 2026 and 2025, there were $30,954 and $26,849, respectively, of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the plans. As of June 30, 2026, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.55 years. The Company estimates that share-based compensation expense for the year ended December 31, 2026 will be $21,291.
Repurchases of Common Stock
On December 9, 2025, the Company's Board of Directors approved a stock repurchase program (the "December 2025 program"), which replaced the previously approved June 1999 program. The December 2025 program authorizes the repurchases of up to and including 4,000,000 shares of the Company's ordinary shares. This stock repurchase program has no expiration date, does not oblige the Company to acquire any particular amount of the Company's ordinary shares, and may be terminated at any time. Since the inception of the December 2025 program, a total of 342,788 shares have been repurchased.
During the six months ended June 30, 2026 and 2025, the Company purchased 273,129 and 237,834 shares, respectively, from open market purchases and from employees in connection with the tax settlement of vested shares and/or exercised stock options, as applicable, under the Company's omnibus incentive plan. These shares were purchased at an average cost of $163.15 and $162.25 per share, respectively. The Company records the applicable excise taxes payable related to repurchases of our common stock as an incremental cost of the shares repurchased and a corresponding liability for the excise tax payable in "Other accrued liabilities" on our condensed consolidated balance sheet. The excise tax payable was $161 and $779 as of June 30, 2026 and December 31, 2025, respectively.